Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting
- BOULDER, Colo. , April 2, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced the Company will present five posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois.
- 04/02/2025
|
Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
- Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues Expected monotherapy and combination data from the ELVN-002 Phase 1 trials in second half of 2025 Strong balance sheet with $313 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into mid-2027 BOULDER, Colo. , Mar. 13, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update, including highlights of pipeline progress.
- 03/13/2025
|
Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
- BOULDER, Colo. , Feb. 25, 2025 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 10:30 a.m.
- 02/25/2025
|
Biotech walks a 'tightrope' amid unclear funding, regulations
- Earlier this week, the Trump administration froze and then rescinded the freeze on federal funding for several programs, including research funding that the biotech industry relies on. Clear Street senior equity analyst and director of research, Mara Goldstein, sits down with Julie Hyman and Josh Lipton on Market Domination to discuss how to play the biotech sector as Trump's second term in the White House is underway.
- 01/30/2025
|
Enliven's Early Data Stands Out From Peers
- Enliven Therapeutics' ELVN-001 shows promising interim data, achieving a 44% major molecular response rate in heavily pre-treated CML patients within 12 weeks. ELVN-001 targets the BCR-ABL gene fusion, addressing resistance issues seen with other TKIs, including the T315I mutation. Financially, Enliven has a market cap of $1.9bn and a cash runway of 7–8 quarters, supporting continued R&D efforts.
- 01/07/2025
|
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update
- Announced positive data from the Phase 1 clinical trial of ELVN-001 in CML, reporting a cumulative MMR rate of 44% (8/18) by 24 weeks and showing that ELVN-001 remains well-tolerated with no dose reductions Continued to progress ELVN-002 with a focus on recently initiated combination clinical trials evaluating patients with HER2+ MBC and CRC Strong balance sheet with $292 million in cash, cash equivalents and marketable securities, which is expected to provide cash runway into late 2026 BOULDER, Colo. , Nov. 13, 2024 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today reported financial results for the third quarter ended September 30, 2024, and provided a business update, including highlights of pipeline progress.
- 11/13/2024
|
Enliven Therapeutics to Present at the Jefferies London Healthcare Conference
- BOULDER, Colo. , Nov. 7, 2024 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 9:30 a.m.
- 11/07/2024
|
Why Enliven is this analyst's top biotech stock pick
- Salim Syed, Mizuho Americas managing director and senior analyst, joins the latest edition of Good Buy or Goodbye to discuss his top and bottom picks in the pharmaceutical industry. Syed points to Enliven Therapeutics (ELVN) as his top pick, believing that its drugs in development are promising.
- 10/18/2024
|
Enliven Therapeutics, Inc. (ELVN) Is a Great Choice for 'Trend' Investors, Here's Why
- Enliven Therapeutics, Inc. (ELVN) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
- 10/14/2024
|
Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
- Updated Phase 1 data presented at ESH-iCMLf 26 th Annual John Goldman Conference Reported cumulative MMR rate of 44% (8/18) by 24 weeks, with stable or deepening responses between weeks 12 and 24, which continues to compare favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs ELVN-001 remains well-tolerated with no dose reductions reported with 39 patients enrolled and a median treatment duration of 20 weeks at cutoff BOULDER, Colo., Sept. 28, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced updated, positive data from the Phase 1 clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia (CML) that has failed, or the patient is intolerant to or not a candidate for, available therapies known to be active for treatment of their CML (NCT05304377) at the European Society of Hematology International Chronic Myeloid Leukemia Foundation (ESH-iCMLf) 26th Annual John Goldman Conference.
- 09/28/2024
|
Here's Why Momentum in Enliven Therapeutics, Inc. (ELVN) Should Keep going
- Enliven Therapeutics, Inc. (ELVN) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
- 09/26/2024
|
Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML
- BOULDER, Colo., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced details for the updated ELVN-001 Phase 1a data, which was selected for an oral presentation at the upcoming European Society of Hematology International Chronic Myeloid Leukemia Foundation (ESH-iCMLf) 26th Annual John Goldman Conference taking place September 27-29 in Prague, Czech Republic.
- 09/18/2024
|
Wall Street Analysts See a 58.78% Upside in Enliven Therapeutics, Inc. (ELVN): Can the Stock Really Move This High?
- The average of price targets set by Wall Street analysts indicates a potential upside of 58.8% in Enliven Therapeutics, Inc. (ELVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
- 09/04/2024
|
Wall Street Analysts Think Enliven Therapeutics, Inc. (ELVN) Could Surge 43.04%: Read This Before Placing a Bet
- The consensus price target hints at a 43% upside potential for Enliven Therapeutics, Inc. (ELVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
- 08/16/2024
|
Enliven Therapeutics to Present at Two Upcoming Investor Conferences
- BOULDER, Colo., May 29, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced that management will present at the following investor conferences in June:
- 05/29/2024
|
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update
- Announced positive proof of concept data from Phase 1 clinical trial of ELVN-001 in CML, achieving an initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients
- 05/14/2024
|
Enliven Therapeutics shares rise on promising preliminary data for blood cancer drug
- Enliven Therapeutics spiked to a 52-week high after the precision oncology firm unveiled positive proof of concept data from an early-stage trial of its blood cancer therapeutic. The company released data from its Phase 1 clinical trial evaluating its drug candidate ELVN-001 in patients with chronic myeloid leukemia (CML) who are relapsed, refractory, or intolerant to available tyrosine kinase inhibitors (TKIs).
- 04/11/2024
|
Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
- Achieved initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients, which compares favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs
- 04/11/2024
|
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors
- BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced the appointment of Lori Kunkel, MD, to its Board of Directors. Dr. Kunkel brings more than twenty-five years of experience in oncology and immunology drug development and commercialization to the Board.
- 04/09/2024
|
Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024
- BOULDER, Colo., March 28, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced it will host a webcast on Thursday, April 11, 2024, at 8:00 a.m. ET to discuss initial proof of concept data on ELVN-001 and the evolving chronic myeloid leukemia (CML) landscape. ELVN-001 is a highly selective, small molecule kinase inhibitor designed to specifically target the ATP-pocket of the BCR-ABL gene fusion, the oncogenic driver for patients with CML.
- 03/28/2024
|
Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updates
- Financing includes participation from new and existing investors Net proceeds, along with existing cash, cash equivalents and marketable securities, are expected to extend cash runway into late 2026 and through multiple key clinical milestones for ELVN-001 and ELVN-002 Company to host an event with KOLs on April 11, 2024, to discuss initial proof of concept data from a Phase 1a trial evaluating ELVN-001 in adults with chronic myeloid leukemia (CML) BOULDER, Colo., March 19, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced that it has entered into a securities purchase agreement for a private investment in public equity (PIPE) financing that is expected to result in gross proceeds of approximately $90 million, before deducting offering expenses.
- 03/19/2024
|
Enliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
- Initial proof of concept data from Phase 1a trial evaluating ELVN-001 in adults with chronic myeloid leukemia (CML) is expected in the second quarter of 2024
- 03/14/2024
|
Enliven Therapeutics to Present at TD Cowen's 44th Annual Health Care Conference
- BOULDER, Colo., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced that management will participate in a panel discussion at TD Cowen's 44th Annual Health Care Conference in Boston, MA, on Tuesday, March 5, 2024, at 12:50 p.m. ET.
- 02/27/2024
|
Enliven Therapeutics: Preclinical Company With Interesting Value Proposition
- Enliven Therapeutics, Inc. is a recently merged biopharma company focused on developing oncology candidates for leukemia and lymphoma. The company has raised $165 million in a private placement to fund its pipeline, which includes two phase 1 candidates. ELVN-001 targets chronic myeloid leukemia and shows promise in preclinical tests, while ELVN-002 is a selective HER2 inhibitor with potential in HER2-driven cancers.
- 08/18/2023
|
Enliven Therapeutics Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
- Continued progress of parallel lead programs, ELVN-001 and ELVN-002, through dose escalation in Phase 1 trials, with initial proof of concept data for both programs expected in 2024
- 08/10/2023
|
Biotech Hasn't Been This Blazing Hot Since Early 2021 — Here Are The Top 5
- The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
- 08/04/2023
|
The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks
- The top five biotech stocks today have several commonalities. Among them are strong ratings.
- 08/04/2023
|
Enliven Therapeutics to Present at Two Upcoming Investor Conferences
- BOULDER, Colo., May 31, 2023 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced that management will present at the following investor conferences in June:
- 05/31/2023
|
The Cream Of The Crop: 5 Biotech Stocks That Outrank 91% Of All Stocks
- The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
- 03/24/2023
|
Penny Stocks To Buy This Week? 7 Short Squeeze Stocks To Watch
- Short squeeze penny stocks to watch this week. The post Penny Stocks To Buy This Week?
- 01/06/2023
|
3 Best Penny Stocks To Buy Before November According To Insiders
- Penny stocks to buy according to insiders in October. The post 3 Best Penny Stocks To Buy Before November According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 10/20/2022
|
New to Trading Penny Stocks? Must Knows in 2022
- Are these methods part of your penny stocks trading strategy The post New to Trading Penny Stocks? Must Knows in 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 10/16/2022
|
Imara (IMRA) Stock Soars 35% on Merger Agreement
- Imara (NASDAQ: IMRA ) stock is rocketing higher on Friday after the company revealed plans for a merger agreement with Enliven Therapeutics. The merger agreement will involve no cash and instead see the two companies use stock to fuel the deal.
- 10/14/2022
|
Imara: Potential Liquidation
- Imara has announced strategic alternatives and has announced the sale its key asset. It now trades 37% below its Pro Forma net cash levels and a liquidation would be ideal.
- 09/29/2022
|
Has IMARA (IMRA) Outpaced Other Medical Stocks This Year?
- Here is how IMARA Inc. (IMRA) and Viracta (VIRX) have performed compared to their sector so far this year.
- 09/16/2022
|
3 High Volume Penny Stocks To Watch Before Next Week
- Here's what you need to know about buying penny stocks on September 9th, 2022 The post 3 High Volume Penny Stocks To Watch Before Next Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 09/09/2022
|
10 Top Penny Stocks With Unusual Options Activity This Week
- Penny stocks to watch today with unusual options action. The post 10 Top Penny Stocks With Unusual Options Activity This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 09/08/2022
|
Looking for Popular Penny Stocks to Buy? 3 to Watch Now
- Which penny stocks are you buying today? The post Looking for Popular Penny Stocks to Buy?
- 09/08/2022
|
5 Top Penny Stocks With Unusual Options Activity Today
- Penny stocks to watch with unusual options activity today. The post 5 Top Penny Stocks With Unusual Options Activity Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 09/07/2022
|
What Makes IMARA Inc. (IMRA) a New Buy Stock
- IMARA Inc. (IMRA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 05/19/2022
|
Read Why Imara Shares Are Falling Today
- Imara Inc (NASDAQ: IMRA) shares are falling after interim analyses of its Ardent Phase 2b trial of tovinontrine (IMR-687) in sickle cell disease (SCD) and Forte Phase 2b trial in beta-thalassemia. Data from the sickle cell disease study interim analysis demonstrated that.
- 04/05/2022
|
Imara (IMRA) CEO, Rahul Ballal on Q4 2021 Results - Earnings Call Transcript
- Imara (IMRA) CEO, Rahul Ballal on Q4 2021 Results - Earnings Call Transcript
- 03/15/2022
|
7 Biotech Stocks With Key Catalysts in March
- These seven stocks have some key catalysts lined up for March with the potential to move their price actions in big ways. The post 7 Biotech Stocks With Key Catalysts in March appeared first on InvestorPlace.
- 03/09/2022
|
Imara to Webcast Conference Call of Full Year 2021 Financial Results and Business Highlights
- BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare hemoglobin disorders and other serious diseases, today announced that the company will host a conference call and live webcast on Tuesday, March 15, at 8:30 a.m. ET to discuss its financial results for the year ended December 31, 2021 and review recent business highlights.
- 03/08/2022
|
Best Penny Stocks To Buy? 3 To Watch With Insider Buying In February
- Insiders are scooping up these penny stocks in February. The post Best Penny Stocks To Buy?
- 02/21/2022
|
Imara to Present at 11th Annual SVB Leerink Global Healthcare Conference
- BOSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare hemoglobin disorders and other serious diseases, today announced that Rahul Ballal, Ph.D., President and Chief Executive Officer, will participate in a Fireside Chat at the 11th Annual SVB Leerink Global Healthcare Conference taking place virtually on Thursday, February 17, 2022 at 3:40 p.m. ET.
- 02/10/2022
|
Imara To Start Testing Tovinontrine In Heart Failure Patients
- The FDA signed off Imara Inc's (NASDAQ: IMRA) investigational new drug (IND) application for tovinontrine (IMR-687) in heart failure with preserved ejection fraction (HFpEF). The Company plans to initiate a Phase 2 trial in Q2 of 2022 to evaluate tovinontrine in patients 45 years of age or older with persistent HFpEF symptoms.
- 01/25/2022
|
Imara to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
- BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, today announced that Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara, will present at the H.C. Wainwright BioConnect 2022 Virtual Conference being held January 10–13, 2022.
- 01/05/2022
|
Imara Changes Primary Endpoint In Mid-Stage Sickle Cell Disease Trial
- Imara Inc (NASDAQ: IMRA) has announced a change to the primary endpoint for the Ardent Phase 2 trial of tovinontrine (IMR-687) in sickle cell disease. Imara is a biopharmaceutical company focused on therapeutics for rare inherited genetic disorders of hemoglobin.
- 11/22/2021
|
7 Penny Stocks to Book Profits on Before 2022
- Penny stocks can turn a quick profit. These 7 picks are designed to do so before the end of this year and cover multiple sectors.
- 11/16/2021
|
IMARA Inc. (IMRA) CEO Rahul Ballal on Q3 2021 Results - Earnings Call Transcript
- IMARA Inc. (IMRA) CEO Rahul Ballal on Q3 2021 Results - Earnings Call Transcript
- 11/09/2021
|
Imara to Present Clinical and Preclinical Data at the American Society of Hematology (ASH) Annual Meeting 2021
- Tovinontrine (IMR-687) VOC data in patients with sickle cell disease from ongoing Phase 2a open-label extension study and preclinical models of beta-thalassemia to be presented
- 11/04/2021
|
Imara to Participate in Upcoming Investor Conferences
- SVB Leerink CybeRx Series and 2021 Cantor Virtual Global Healthcare Conference SVB Leerink CybeRx Series and 2021 Cantor Virtual Global Healthcare Conference
- 09/15/2021
|
Imara to Present at Upcoming Investor Conferences
- Citi 16th Annual BioPharma Virtual Conference, H.C. Wainwright 23rd Annual Global Investment Conference and Morgan Stanley 19th Annual Global Healthcare Conference Citi 16th Annual BioPharma Virtual Conference, H.C. Wainwright 23rd Annual Global Investment Conference and Morgan Stanley 19th Annual Global Healthcare Conference
- 09/03/2021
|
IMARA's (IMRA) CEO Rahul Ballal on Q2 2021 Results - Earnings Call Transcript
- IMARA's (IMRA) CEO Rahul Ballal on Q2 2021 Results - Earnings Call Transcript
- 08/08/2021
|
Imara Reports Second Quarter 2021 Financial Results and Business Highlights
- Accelerated enrollment in Phase 2b trials in sickle cell disease and beta-thalassemia; interim analyses expected in fourth quarter of 2021
- 08/06/2021
|
Imara Announces Completion of Patient Enrollment in Ardent Phase 2b Clinical Trial of IMR-687 (tovinontrine) for Sickle Cell Disease
- Interim analysis expected in fourth quarter of 2021 and primary endpoint readout now expected in first quarter of 2022 Interim analysis expected in fourth quarter of 2021 and primary endpoint readout now expected in first quarter of 2022
- 08/05/2021
|
Imara to Webcast Conference Call of Second Quarter 2021 Financial Results and Business Highlights
- BOSTON, July 30, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the company will host a conference call and live webcast on Friday, August 6, 2021, at 8:30 a.m. ET to discuss its financial results for the quarter ended June 30, 2021 and review recent business highlights.
- 07/30/2021
|
Imara Announces Pricing of Public Offering
- BOSTON, July 13, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (the “Company”) (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, announced the pricing of its previously announced underwritten public offering of shares of its common stock at a public offering price of $6.00 per share, for gross proceeds of $50 million, before underwriting discounts and commissions and offering expenses payable by the Company. The offering is expected to close on July 16, 2021, subject to customary closing conditions. All shares are being offered by the Company. In addition, the Company has granted the underwriters an option for a period of 30 days to purchase up to $7.5 million of additional shares of its common stock at the public offering price, less underwriting discounts and commissions.
- 07/13/2021
|
Biotech Losers In 2021 That Could Bounce Big In The Second Half
- Biotech stocks are tricky investment bets that require careful analysis and scrutiny. A stock that has fallen off a cliff in reaction to a binary event can neither be written off entirely nor picked as a bargain buy.
- 07/03/2021
|
Imara Announces Recipients of the Second Annual Real Impact Grants Program to Support People Affected by Rare Genetic Blood Disorders
- Imara has continued and expanded the program to award 30 grants totaling $150,000 to fund nonprofit, community-based organizations supporting individuals with sickle cell disease and beta-thalassemia Imara has continued and expanded the program to award 30 grants totaling $150,000 to fund nonprofit, community-based organizations supporting individuals with sickle cell disease and beta-thalassemia
- 06/17/2021
|
Imara Presents Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress
- Final data from 93-patient Phase 2a clinical trial show lower annualized rate of vaso-occlusive crises (VOCs) and longer time to first VOC on IMR-687
- 06/11/2021
|
2 Falling Knives to Catch
- Unexpectedly, Wall Street recommends acquiring shares of Protara Therapeutics Inc ( TARA , Financial) and IMARA Inc ( IMRA , Financial), despite the fact that these two equities have shown poor performance over the prior 52 weeks through June 3. With positive recommendations despite the share price tumble, these two stocks have earned the nickname "falling knives.
- 06/04/2021
|
Imara to Present Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress
- Oral presentation provides final results from 93-patient Phase 2a trial and additional interim data from open label extension trial
- 06/04/2021
|
Imara, Inc. (IMRA) CEO Rahul Ballal on Q1 2021 Results - Earnings Call Transcript
- Imara, Inc. (IMRA) CEO Rahul Ballal on Q1 2021 Results - Earnings Call Transcript
- 05/11/2021
|
Imara Announces Opening of Higher Dose Arms in Global Phase 2b Clinical Trials of IMR-687 for Sickle Cell Disease and Beta-Thalassemia
- Independent Data Monitoring Committees endorse opening higher dose IMR-687 treatment arms in ongoing Ardent and Forte Phase 2b clinical trials after review of safety and tolerability data at lower doses
- 03/17/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of IMARA, Inc. - IMRA
- New York, New York--(Newsfile Corp. - March 14, 2021) - Pomerantz LLP is investigating claims on behalf of investors of IMARA, Inc. ("IMARA" or the "Company") (NASDAQ: IMRA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether IMARA and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the...
- 03/14/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of IMARA, Inc. - IMRA
- NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of IMARA, Inc. ("IMARA" or the "Company") (NASDAQ: IMRA). Such investors are advised to contact Robert S.
- 03/12/2021
|
Imara, Inc. (IMRA) CEO Rahul Ballal on Q4 2020 Results - Earnings Call Transcript
- Imara, Inc. (IMRA) CEO Rahul Ballal on Q4 2020 Results - Earnings Call Transcript
- 03/05/2021
|
Imara Reports Full Year 2020 Financial Results and Business Highlights
- Significant progress advancing IMR-687 as an oral, once-a-day potentially disease modifying treatment for sickle cell disease and beta-thalassemia
- 03/05/2021
|
Imara to Webcast Conference Call of Full Year 2020 Financial Results and Business Highlights
- BOSTON, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the company will host a conference call and live webcast on Friday, March 5, 2021 at 8:30 a.m. ET to discuss its financial results for the year ended December 31, 2020 and review recent business highlights.
- 02/26/2021
|
Imara to Present at SVB Leerink 10th Annual Global Healthcare Conference
- BOSTON, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that Rahul Ballal, Ph.D., President and Chief Executive Officer, will participate in a Fireside Chat at the SVB Leerink 10th Annual Global Healthcare Conference on Friday, February 26, from 1:40-2:10 p.m. ET.
- 02/19/2021
|
Imara Announces the Appointment of Kenneth Attie, M.D. as Chief Medical Officer
- Brings 30 years of medical research experience within the biopharmaceutical industry, including Acceleron Pharma and Genentech Brings 30 years of medical research experience within the biopharmaceutical industry, including Acceleron Pharma and Genentech
- 01/20/2021
|
Imara Analyst Says Buy The Weakness Ahead Of Multiple 2021 Data Readouts
- Imara Inc (NASDAQ: IMRA) shares took a thrashing Wednesday following the release of mid-stage results of its IMR-687 in sickle cell disease. Underwhelming Data: IMR-687 failed to close part of the gap from the 1.7% absolute increase in fetal hemoglobin, or HbF, demonstrated at interim readout and the 3% responder threshold agreed to by the FDA as a potential surrogate endpoint in sickle cell disease studies.
- 01/06/2021
|
Imara Presents IMR-687 Phase 2a Open Label Extension Case Reports on Two Patients with Sickle Cell Disease at the 62nd ASH Annual Meeting and Exposition
- Preliminary data as of August 2020 from ongoing Phase 2a o pen l abel e xtension trial s howed increase s in HbF percentage and F-cell s after approximately six months of treatment
- 12/07/2020
|
Imara to Present Clinical Data on IMR-687 as Monotherapy and in Combination with Hydroxyurea in Patients with Sickle Cell Disease at the 62nd ASH Annual Meeting and Exposition
- BOSTON, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that clinical data from the ongoing IMR-687 Phase 2a open label extension (OLE) clinical trial in adult patients with sickle cell disease (SCD) will be presented at the 62 nd American Society of Hematology (ASH) Annual Meeting and Exposition to be held virtually December 5-8, 2020.
- 11/30/2020
|
Imara Announces the Appointment of Lynette Hopkinson as Senior Vice President of Regulatory
- Brings 25 years of experience in the pharmaceutical and biotech industries and a deep understanding of global regulatory strategy and commercial regulatory affairs Brings 25 years of experience in the pharmaceutical and biotech industries and a deep understanding of global regulatory strategy and commercial regulatory affairs
- 11/17/2020
|
IMARA Inc.'s (IMRA) CEO Rahul Ballal on Q3 2020 Results - Earnings Call Transcript
- IMARA Inc.'s (IMRA) CEO Rahul Ballal on Q3 2020 Results - Earnings Call Transcript
- 11/07/2020
|
Imara Reports Third Quarter 2020 Financial Results and Business Highlights
- Patient Dosing Underway in Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia
- 11/05/2020
|
Imara to Webcast Conference Call of Third Quarter Financial Results
- BOSTON, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the company will host a conference call and live webcast on Thursday, November 5, 2020, at 8:30 a.m. ET to discuss its third quarter 2020 financial results and recent business highlights.
- 10/29/2020
|
Thalassemia Treatment Market Size, 2020 Growth, Types, Trends, Size, Share and Top Key Players by Forecast Research 2025
- Oct 06, 2020 (Heraldkeepers) --
Global Thalassemia Treatment Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2019-2025. Rise in...
- 10/06/2020
|
Europe Thalassemia Market and Competitive Landscape Report 2020: Epidemiology, Key Products Marketed, Market Valuations and Forecast, Drugs Sales and Market Shares 2016-2024 - ResearchAndMarkets.com
|
U.S. IPO Week Ahead: No IPOs, But Plenty Of Potential Launches In The Short Holiday Week
- Just one SPAC is scheduled for the week ahead. More SPACs may join the IPO calendar, and another wave of new filings will likely hit after Labor Day as well.
- 09/06/2020
|
Wall Street Breakfast: The Week Ahead
- Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify.
- 09/06/2020
|
Stocks To Watch: Tech Reboots And Eyes On Lululemon, Peloton & GameStop
- Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
- 09/05/2020
|
TG Therapeutics Umbralisib Development, And Other News: The Good, Bad And Ugly Of Biopharma
- TG Therapeutics reports development for Umbralisib. Mesoblast gets FDA nod for Ryoncil.
- 08/14/2020
|
The Daily Biotech Pulse: Adcom Rules In Favor Of Mesoblast, CureVac IPO, Novavax Clinches UK COVID-19 Vaccine Deal
- Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 13) * Aerpio Pharmaceuticals Inc (NASDAQ: ARPO) * Fulgent Genetics Inc (NASDAQ: FLGT) * GENMAB A/S/S ADR (NASDAQ: GMAB) * Halozyme Therapeutics, Inc. (NASDAQ: HALO) * Inozyme Pharma Inc (NASDAQ: INZY) * iTeos Therapeutics Inc (NASDAQ: ITOS) * Mirati Therapeutics Inc (NASDAQ: MRTX) * Natera Inc (NASDAQ: NTRA) * Nurix Therapeutics Inc (NASDAQ: NRIX) * Orthopediatrics Corp (NASDAQ: KIDS) * Penumbra Inc (NYSE: PEN) * Rocket Pharmaceuticals Inc (NASDAQ: RCKT) * Silk Road Medical Inc (NASDAQ: SILK) * TFF Pharmaceuticals Inc (NASDAQ: TFFP) * Vaxcyte Inc (NASDAQ: PCVX)Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 13) * Entera Bio Ltd (NASDAQ: ENTX) * Forma Therapeutics Holdings Inc (NASDAQ: FMTX)(reacted to its second-quarter results) * Lantern Pharma Inc. (NASDAQ: LTRN) * NanoVibronix Inc (NASDAQ: NAOV) * Recro Pharma Inc (NASDAQ: REPH)Stocks In Focus Novavax Agrees to Supply 60M Doses of Coronavirus Vaccine to U.K. Novavax, Inc. (NASDAQ: NVAX) said it has signed a term sheet with the U.K. for supplying 60 million doses of NVX-CoV2373, its COVID-19 vaccine candidate. The company has also agreed with the government regarding a Phase 3 clinical trial to assess the efficacy of the vaccine in the U.K. population.Novavax said it will also expand its collaboration with FUJIFILM Diosynth Biotechnologies, which will manufacture the antigen component of NVX-CoV2373 from its Billingham, Stockton-on-Tees site in the U.K., in addition to its sites in North Carolina and Texas in the U.S.The company has been stitching up partnerships for manufacturing as well as the supply of the vaccine, as it looks to scale manufacturing ahead of a potential emergency use authorization or approval.In pre-market trading, the stock rose 6.53% to $141.98.Imara Begins Dosing Patients In a Phase 2a Study of Sickle Cell Disease Imara Inc (NASDAQ: IMRA) said it has dosed the first patient in its Ardent Phase 2b clinical trial of IMR-687 for adult patients with sickle cell disease."Dosing of the first patient in the Ardent clinical trial represents a critical step forward as we advance IMR-687 into Phase 2b testing, a clinical trial that will test higher doses and longer durations of IMR-687," said Rahul Ballal, CEO of Imara.The stock rose 3.91% to $21 in after-hours trading.Kamada Up Big Despite No Catalyst Shares of Israeli plasma-derived biopharma Kamada Ltd. (NASDAQ: KMDA) were advancing solidly. Monday, the company announced the commencement of a Phase 1/2 study of its anti-SARS-CoV-2 plasma-derived immunoglobulin product as a potential treatment for COVID-19 in Israel. Wednesday, the company reported its second-quarter results, showing below consensus bottom-line results and a decline in revenues, which led to some selling in the stock in the session.The stock jumped 43% to $12.87 in after-hours trading.Mesoblast Stem Cell Therapy For Pediatric Acute Graft-versus-host Disease Endorsed by FDA Panel Mesoblast limited (NASDAQ: MESO) shares, which were halted for trading Thursday, pending announcement on an Adcom verdict, are likely to move higher after it said FDA's Oncologic Drugs Advisory Committee voted overwhelmingly in favor that the available data support the efficacy of remestemcel-L in pediatric patients with steroid-refractory acute graft versus host disease.The investigational therapy, which goes by the trade name Ryoncil, has a PDUFA action date of Sept.30, and the company said it expects the launch the therapy in the U.S. in 2020.TFF Pharma Executes Licensing Agreement For TFF Technology For Up to $210M TFF Pharmaceuticals said it has entered into a worldwide exclusive licensing agreement with Union therapeutics, which provides for the latter acquiring an option to obtain a worldwide exclusive license of former's TFF technology to be used in the field of niclosamide, including oral and inhalation versions of niclosamide, potentially for COVID-19, as well as other niclosamide-based therapies.Subject to Union's exercise of its option, it has agreed to pay TFF potential development, regulatory and sales-related milestone payments of up to $210 million. Union will also pay TFF tiered single-digit royalties on product sales.The companies have also agreed to collaborate on securing government support for funding the development of niclosamide-based products for the treatment of COVID-19.The stock rallied 23.83% to $12.73 in after-hours trading.Earnings Navidea Biopharmaceuticals Inc (NYSE: NAVB) reported second-quarter revenues of $271,000 compared to $260,000 a year ago. The net loss per share narrowed from 27 cents to 11 cents compared to the 12-cent per share consensus loss estimate.View more earnings on IBBThe stock climbed 18.30% to $3.75 in after-hours trading.Molecular diagnostics company Myriad Genetics, Inc. (NASDAQ: MYGN) reported a 57% year-over-year decline in fiscal year fourth-quarter revenues to $93.2 million. The company reversed to a loss of 31 cents per share on a non-GAAP basis from a profit of 41 cents per share.The company also announced the appointment of Paul Diaz as president and CEO, effective August 13, 2020. He will also serve on the board, it added.Caladrius Biosciences Inc (NASDAQ: CLBS) reversed from a loss of 49 cents in the second quarter of 2019 to a profit of 50 cents per share in 2020, thanks to a benefit from income taxes.In after-hours trading, the stock added 6.05% to $2.28.Co-Diagnostics Inc (NASDAQ: CODX) reported second-quarter revenues of $24.04 million, up from $61,574 reported for the year-ago period. The company reversed from a loss of 8 cents per share to a profit of 43 cents per share, which however, trailed the 59-cent per share consensus estimate.In after-hours trading, the stock slumped 16.24% to $17.59.Offerings Equillium Inc (NASDAQ: EQ) said it has priced its underwritten public offering of 5 million shares of common stock at $7 per share. Equillium said it expects to use the gross proceeds from the offering to be about $35 million. The offering is expected to close on or about August 18.The stock slipped 15.53% to $7.45 in after-hours trading.OptiNose Inc (NASDAQ: OPTN) announced the commencement of a proposed underwritten public offering of shares of its common stock. All of the shares of common stock are to be offered by the company.Optinose said it intends to use the net proceeds of the offering for working capital and general corporate purposes, including the commercialization of Xhance, the clinical development of Xhance for a follow on indication for the treatment of chronic sinusitis and the clinical development of OPN-019 for the treatment of COVID-19.In after-hours trading, the stock fell 13.04% to $5.90.On The Radar Earnings PLx Pharma Inc (NASDAQ: PLXP) (before the market open) Ocugen Inc (NASDAQ: OCGN) (before the market open) Titan Pharmaceuticals, Inc. common stock (NASDAQ: TTNP Bio-Path Holdings Inc (NASDAQ: BPTH) (before the market open) BioXcel Therapeutics Inc (NASDAQ: BTAI) (before the market open) Soligenix, Inc. Common Stock (NASDAQ: SNGX) (before the market open) Imara (before the market open) Thermogenesis Holdings Inc (NASDAQ: THMO) (after the close)IPO German biotech firm CureVac, which is developing a mRNA vaccine for the novel coronavirus, priced its initial public offering of 13.33 million shares at $16 apiece, raising gross proceeds of about $213.3 million. The company previously estimated a price range of $16. The shares will begin trading on the Nasdaq under the ticker symbol CVAC. Recently, GlaxoSmithKline plc (NYSE: GSK) took a 10% stake in the company.See more from Benzinga * The Daily Biotech Pulse: Mesoblast Awaits Adcom Test, BioCryst Rallies On Insider Buying, Sorrento Hits Back At Short Seller * The Daily Biotech Pulse: India Globalization Gets Nod For Alzheimer's Trial, Moderna's Vaccine Deal With US, Cellular Biomedicine To Go Private * The Daily Biotech Pulse: Regulatory Setback For Fennec Pharma, Ligand To Buy Pfenex, Inovio Says Phase 2/3 Coronavirus Vaccine Study Starts In September(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 08/14/2020
|
IMARA Inc.'s (IMRA) CEO Rahul Ballal on Q2 2020 Results - Earnings Call Transcript
- IMARA Inc. (NASDAQ:IMRA) Q2 2020 Results Earnings Conference Call August 14, 2020, 08:30 AM ET Company Participants Rahul Ballal - Chief Executive Officer Michael Gray - Chief Financial and Chief Operating Officer Conference Call Participants Yigal Nochomovitz - Citi Group Joseph Schwartz - SVB Leerink Presentation Operator Ladies and gentlemen, thank you for standing by and welcome to the IMARA Inc.
- 08/14/2020
|
Imara Reports Second Quarter 2020 Financial Results and Business Highlights
- Initiated Phase 2b clinical trials of IMR-687 in sickle cell disease and beta-thalassemia; First patient dosed in Ardent Phase 2b sickle cell clinical trialReported Phase 2a interim safety and efficacy data at the European Hematology Association Annual Congress and promising clinical outcomes in an Open Label Extension Study that tests IMR-687 for longer durationIMR-687 granted Orphan Drug, Fast Track and Rare Pediatric designations by the FDA for beta-thalassemia Company to host conference call and live webcast today at 8:30 a.m. ETBOSTON, Aug. 14, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today reported financial results for the second quarter ended June 30, 2020 and reviewed recent business highlights.“As we head into the second half of 2020, we are encouraged by several advancements across our programs that bring us closer to providing oral treatment options to patients with rare blood disorders,” said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara. “We initiated our Phase 2b clinical trials for IMR-687 in both sickle cell disease and beta-thalassemia and dosed the first patient in our Ardent Phase 2b clinical trial for adult patients with sickle cell disease. We also reported encouraging Phase 2a interim clinical trial results with IMR-687 at the European Hematology Association Annual Congress and more recently observed promising clinical outcomes with longer duration IMR-687 treatment as part of our Phase 2a open label extension trial. In addition, we made important progress on the regulatory front as we were granted Orphan Drug, Fast Track and Rare Pediatric designations by the FDA for the treatment of patients with beta-thalassemia. Finally, we are leveraging IMR-687’s differentiated mechanism of action and began preclinical studies to explore its potential for the treatment of heart failure with preserved ejection fraction, or HFpEF.”Dr. Ballal continued, “We look forward to further advancing patient recruitment activities for our Phase 2b clinical trials and expect to report top-line data from our ongoing Phase 2a clinical trial in sickle cell disease during the fourth quarter of 2020.” Recent Corporate Highlights and Updates * Presented Clinical Data from Phase 2a and Phase 2a Open Label Extension Clinical Trials: Imara presented interim Phase 2a clinical trial results for IMR-687 in adult patients with sickle cell disease (SCD) at the virtual 25th European Hematology Association (EHA) Annual Congress in June 2020. The data from this ongoing clinical trial demonstrated that IMR-687 was well tolerated as a monotherapy and in combination with hydroxyurea (HU). In the higher dose cohort, IMR-687 monotherapy showed a statistically significant (p =0.022) increase in the number of F-cells, which are red blood cells containing fetal hemoglobin (HbF), as well as a dose-dependent increase in HbF levels in adult patients with SCD. In addition, two adult patients with SCD have passed six-months of treatment in the Company’s ongoing Phase 2a open label extension (OLE) clinical trial (one at six months and one at twelve months). A review of outcomes for these two patients indicate potential benefits of IMR-687 with respect to reported vaso-occlusive crises (VOCs) trends, healthcare facility use, and SCD associated biomarkers. Enrollment in the OLE has also recently increased as the Phase 2a trial is completing, with six of eight patients entering this four-year safety study since the beginning June 2020. * Initiated Clinical Trials: Imara initiated Phase 2b clinical trials of IMR-687 in SCD and adult patients with beta-thalassemia. Patient screening is underway in both trials, and the Company dosed the first patient in its Ardent Phase 2b SCD clinical trial and expects to begin dosing in the beta-thalassemia trial in the near-term. * IMR-687 Granted Multiple Regulatory Designations: The FDA granted IMR-687 Orphan, Fast Track and Rare Pediatric Disease designations for the treatment of patients with beta-thalassemia. * Established Advisory Board for Clinical Studies in Africa: Imara established a regional advisory board to guide the execution of IMR-687 clinical studies in Africa, which includes key opinion leaders with expertise treating patients and conducting clinical studies in the region. * Expanded Pipeline: Imara is conducting preclinical research to evaluate the potential of IMR-687 in heart failure with preserved ejection fraction (HFpEF), also referred to as diastolic heart failure. Published literature suggests that inhibition of PDE9, and resulting increases in cyclic guanosine monophosphate (cyclic GMP) through natriuretic peptide modulation, can serve as an attractive target for the prevention and treatment of vascular disease, including HFpEF. Imara has formed an advisory board comprised of key heart failure opinion leaders to further advise on potential development of IMR-687 in this indication. * Initiated Real Impact Program and Funded Community Support Grants: Imara announced the grant recipients of its ‘Real Impact’ community support initiative. This program, which includes grant funding to support nonprofit, community-based organizations serving patients and families impacted by SCD and beta-thalassemia, awarded 25 grants of approximately $5,000 each to community-based organizations in 13 states. The grant funding was increased by 25% from original plans due to the strong demand for COVID-19 related relief programs. * Added to Russell 2000® Index: Imara was added as a member of the U.S. small-cap Russell 2000® Index. Russell U.S. Indexes are widely used by investment managers and institutional investors for passive funds and investment products and as benchmarks for active investment strategies.Second Quarter 2020 Financial Results * Cash Position: Cash, cash equivalents and investments were $106.3 million as of June 30, 2020, as compared to cash, cash equivalents and investments of $28.9 million as of December 31, 2019. * Research and Development Expenses: Research and development expenses were $7.9 million for the second quarter of 2020, as compared to $4.4 million for the second quarter of 2019. The increase of $3.5 million was primarily related to the development and manufacturing of clinical materials, clinical research and oversight of the Company’s clinical trials and investigative fees related to the development of IMR-687, as well as increased personnel-related and other research and development operational costs. * General and Administrative Expenses: General and administrative expenses were $2.4 million for the second quarter of 2020, as compared to $1.2 million for the second quarter of 2019. The increase of $1.2 million was primarily due to increased personnel-related and other general and administrative operational costs as a result of operating as a public company. * Net Loss Attributable to Common Stockholders: Net loss attributable to common stockholders was $10.2 million, or $0.59 per share, for the second quarter of 2020, as compared to a net loss of $5.4 million, or $7.68 per share, for the second quarter of 2019.Financial GuidanceThe Company currently expects that its full-year 2020 research and development expenses will range between $35 million and $40 million and that its full-year 2020 general and administrative expenses will range between $8 million and $10 million. The Company expects that its cash, cash equivalents and investments as of June 30, 2020, will be sufficient to enable it to fund its planned operations into mid-2022.Conference Call and Webcast InformationImara will host a conference call and live webcast today at 8:30 a.m. ET to discuss its second quarter 2020 financial results and other business updates.The live webcast will be available under "Events and Presentations" in the Investors section of the Company's website at imaratx.com. The conference call can be accessed by dialing 1 (833) 519-1307 (U.S. domestic) or +1 (914) 800-3873 (international) and referring to conference ID 9775635. A replay of the webcast will be archived on the Imara website following the presentation.About ImaraImara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia. IMR-687 is being designed to have a multimodal mechanism of action that acts on red blood cells, white blood cells, adhesion mediators and other cell types. For more information, please visit www.imaratx.com.Cautionary Note Regarding Forward-Looking StatementsStatements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements made by Dr.
- 08/14/2020
|
Imara Announces First Patient Dosed in Ardent Phase 2b Clinical Trial of IMR-687 in Sickle Cell Disease
- Highly selective, potent, small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell diseaseBOSTON, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced dosing of the first patient in the company’s Ardent Phase 2b clinical trial of IMR-687 for adult patients with sickle cell disease (SCD). “There remains an unmet need for differentiated oral treatment options for patients with sickle cell disease,” said Jo Howard, M.D., Consultant Haematologist and Honorary Professor in Haemoglobinopathies at Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom, and the national coordinating principal investigator for the Ardent trial. “IMR-687 has demonstrated the potential to directly and selectively inhibit PDE9 and may offer distinct advantages over other therapies, including fetal hemoglobin induction, a multimodal mechanism and a once daily oral dosing regimen. I look forward to leading Guy’s and St Thomas’ participation in this important clinical trial.”“Dosing of the first patient in the Ardent clinical trial represents a critical step forward as we advance IMR-687 into Phase 2b testing, a clinical trial that will test higher doses and longer durations of IMR-687,” said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara. “Specifically, the 300 mg and potentially 400 mg dose levels to be administered in the Ardent trial are designed to provide meaningful exposure to IMR-687 that could be up to two-fold higher than administered in our ongoing Phase 2a clinical trial. We believe that this increased exposure could have a meaningful impact on the therapeutic effect of IMR-687 on patients enrolled in this trial.”Dr. Ballal continued, “I’d like to thank the sickle cell disease community, our clinical trial partners and investigators and the Imara team for their important efforts to support the initiation of this trial amidst the challenges of the global COVID-19 pandemic and the resulting pressures on healthcare systems and access to care.”Imara previously announced data from the second planned interim analysis of its ongoing Phase 2a clinical trial of IMR-687 in adult patients with SCD. Data from this interim analysis demonstrated that IMR-687 was well tolerated as a monotherapy and in combination with hydroxyurea (HU). In the higher dose 100/200 mg cohort, IMR-687 monotherapy showed a statistically significant (p = 0.022) increase in the number of F-cells, which are red blood cells containing fetal hemoglobin (HbF), as well as a dose-dependent increase in HbF levels in adult patients with SCD.Imara expects to report top-line data from this Phase 2a clinical trial in the fourth quarter of 2020. In addition, the company has an ongoing open label extension (OLE) clinical trial, which allows patients from the Phase 2a clinical trial to continue into a long-term, four-year trial to evaluate safety and tolerability of IMR-687. Ardent IMR-687 Phase 2b Clinical Trial Design The global, randomized, double-blind, placebo-controlled, multicenter Ardent Phase 2b clinical trial will enroll approximately 99 adult patients with sickle cell disease (SCD). Patient randomization will be stratified by use of hydroxyurea (HU) as well as by region, and weight-based dosing will be employed to optimize drug exposure and tolerability. The planned primary efficacy objective is to evaluate the proportion of all patients with fetal hemoglobin (HbF) response, defined as an increase of 3% in HbF from baseline to week 24, compared to placebo, and the trial is powered for statistical significance with respect to this endpoint. Patients will continue on treatment through 52 weeks to provide data for planned secondary and additional exploratory endpoints including the evaluation of the effect of IMR-687 versus placebo on HbF-associated biomarkers, indices of red cell hemolysis, white blood cell adhesion, quality of life measures and to measure the incidence of VOCs over the course of a one-year period. In addition, Imara plans to conduct a prespecified interim analysis when 33 patients have reached 24 weeks of treatment. Following the completion of 52 weeks of treatment in the trial, patients will be eligible to enroll in an open-label extension study. For more information about the Ardent trial visit https://clinicaltrials.gov/ct2/show/NCT04474314?cond=Imr-687&draw=2&rank=3.About IMR-687IMR-687 is a highly selective and potent small molecule inhibitor of PDE9. PDE9 selectively degrades cyclic guanosine monophosphate (cGMP), an active signaling molecule that plays a role in vascular biology. Lower levels of cGMP are found in people with SCD and beta-thalassemia and are associated with reduced blood flow, increased inflammation, greater cell adhesion and reduced nitric oxide mediated vasodilation.Blocking PDE9 acts to increase cGMP levels, which is associated with reactivation of fetal hemoglobin (HbF), a natural hemoglobin produced during fetal development. Increased levels of HbF in RBCs have been demonstrated to improve symptomology and substantially lower disease burden in both patients with SCD and patients with beta-thalassemia.About ImaraImara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia. IMR-687 is being designed to have a multimodal mechanism of action that acts on red blood cells, white blood cells, adhesion mediators and other cell types. For more information, please visit www.imaratx.com.Cautionary Note Regarding Forward-Looking StatementsStatements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the statements from Dr. Howard and Dr. Ballal in this press release and statements relating to the (i) expected timing for reporting of data from the ongoing Phase 2a clinical trial evaluating IMR-687 in patients with sickle cell disease and (iii) the Company’s beliefs regarding the strength of its clinical data, the therapeutic potential of IMR-687 and advancement of its clinical program, including with respect to the Phase 2b clinical trial evaluating IMR-687 in patients with sickle cell disease, the Phase 2a clinical trial evaluating IMR-687 in patients with sickle cell disease and the open label extension to the Phase 2a clinical trial. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the impact of extraordinary external events, such as the risks and uncertainties resulting from the impact of the COVID-19 pandemic on the Company’s business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research activities and ability to conduct and readout data from its ongoing Phase 2a clinical trial of IMR-687 in sickle cell disease and the related open label extension trial and its ability to enroll, dose and readout data from its Phase 2b clinical trial of IMR-687 in sickle cell disease; the Company’s ability to advance the development of IMR-687 under the timelines it projects in current and future clinical trials, demonstrate in any current and future clinical trials the requisite safety and efficacy of IMR-687, replicate scientific and non-clinical data in clinical trials, obtain and maintain necessary regulatory approvals, obtain, maintain and enforce necessary patent and other intellectual property protection, identify, enter into and maintain collaboration agreements with third parties, manage competition, manage expenses, raise the substantial additional capital needed to achieve its business objectives, attract and retain qualified personnel, and successfully execute on its business strategies; and other factors discussed in the “Risk Factors” section of the Company’s most recent Quarterly Report on Form 10-Q, which is on file with the Securities and Exchange Commission and in other filings that the Company makes with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Media Contact: Gina Nugent Ten Bridge Communications 617-460-3579 gina@tenbridgecommunications.com Investor Contact: Michael Gray 617-835-4061 mgray@imaratx.com
- 08/13/2020
|
Global Hemoglobinopathy Treatment Drugs Market to Surpass US$ 6.4 Billion by 2027, Says Coherent Market Insights
- The global hemoglobinopathy treatment drugs market is projected to exhibit a CAGR of 8.4% during the forecast period (2020-2027).
- 08/11/2020
|
Imara to Webcast Conference Call of Second Quarter 2020 Financial Results
- BOSTON, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the company will host a conference call and live webcast on Friday, August 14, 2020, at 8:30 a.m. ET to discuss its second quarter 2020 financial results and other business updates. A live webcast will be available under "Events and Presentations" in the Investors section of the company's website at imaratx.com. The conference call can be accessed by dialing 1 (833) 519-1307 (U.S. domestic) or +1 (914) 800-3873 (international) and referring to conference ID 9775635. A replay of the webcast will be archived on the Imara website following the presentation.About Imara Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia. IMR-687 is being designed to have a multimodal mechanism of action that acts on red blood cells, white blood cells, adhesion mediators and other cell types. For more information, please visit www.imaratx.com.Investor Contact: Michael Gray 617-835-4061 mgray@imaratx.com
- 08/07/2020
|
Imricor Announces First Sales Collaboration With Philips
- IMRICOR ANNOUNCES FIRST SALES COLLABORATION WITH PHILIPS.
- 08/04/2020
|
Imricor gets distribution boost in Europe with new Philips deal - Stockhead
- Medical Tech company Imricor (ASX:IMR) continued its rally from March lows with a new distribution agreement this morning. Amid a flurry of 4C filings for the June quarter, Imricor’s announcement made it one of the few small caps this morning with a trading update that moved the needle. The company announced a deal with multinational […]
- 07/31/2020
|
Imara Announces IMR-687 Granted Fast Track Designation and Rare Pediatric Disease Designation for Treatment of Beta-Thalassemia
- BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- IMARA Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation and Rare Pediatric Disease designation for its lead clinical asset, IMR-687, for the treatment of beta-thalassemia. The FDA previously granted Orphan Drug designation for IMR-687 for the treatment of patients with beta-thalassemia and Orphan Drug, Fast Track and Rare Pediatric Disease designations for the treatment of patients with sickle cell disease. “We are pleased to receive from the FDA both Fast Track designation and Rare Pediatric Disease designation for IMR-687. Fast Track designation helps us create the opportunity to potentially accelerate the development of IMR-687 in beta-thalassemia. Rare Pediatric designation reflects the agency’s recognition that beta-thalassemia is a serious disease, with symptoms that manifest in childhood and progress over time into adulthood,” said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara. “We look forward to continuing to advance this novel investigational therapy on behalf of patients in the U.S. and globally living with beta-thalassemia.”Imara recently initiated a Phase 2b clinical trial of IMR-687 in adult patients with beta-thalassemia and expects to dose the first patient in the near-term. Regulatory submissions are underway in 14 countries and screening has initiated for the Phase 2b clinical trial. Imara anticipates initiating pediatric clinical testing in beta-thalassemia after gathering sufficient clinical data in adult patients with beta-thalassemia.About Fast Track Designation The FDA’s Fast Track designation is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. Fast Track designation allows for early and frequent communication with the FDA throughout the entire drug development and review process. It also enables eligibility for Accelerated Approval and Priority Review, as well as a rolling review of a company’s New Drug Application, if relevant criteria are met.About Rare Pediatric Disease Designation Under the FDA’s Rare Pediatric Disease (RPD) program, a sponsor who receives marketing approval for a product with an RPD designation may be eligible for a voucher that can be redeemed to obtain priority review for any subsequent marketing application. The FDA defines a "rare pediatric disease" as a rare disease that affects fewer than 200,000 people in the United States and in which the serious or life-threatening manifestations primarily affect individuals from age zero to 18.About IMR-687 IMR-687 is a highly selective and potent small molecule inhibitor of PDE9. PDE9 uniquely degrades cyclic guanosine monophosphate (cGMP), an active signaling molecule that plays a role in vascular biology. Lower levels of cGMP are often found in people with sickle cell disease and beta-thalassemia and are associated with impaired blood flow, increased inflammation, greater cell adhesion and reduced nitric oxide mediated vasodilation.Blocking PDE9 acts to increase cGMP levels, which are associated with reactivation of fetal hemoglobin, or HbF, a natural hemoglobin produced during fetal development. Increased levels of HbF in red blood cells have been demonstrated to improve symptomology and lower disease burden in patients with sickle cell disease and patients with beta-thalassemia.About Imara Imara Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin. Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia. IMR-687 is being designed to have a multimodal mechanism of action that acts on red blood cells, white blood cells, adhesion mediators and other cell types. For more information, please visit www.imaratx.com.Cautionary Note Regarding Forward-Looking StatementsStatements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements made by Dr. Ballal in this press release and statements relating to the (i) design and timing of the company’s clinical development program for IMR-687 in beta-thalassemia, including the recently initiated Phase 2b clinical trial and (ii) the potential advantages of the Fast Track designation and Rare Pediatric Disease designation by the FDA. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the impact of extraordinary external events, such as the risks and uncertainties resulting from the impact of the COVID-19 pandemic on the Company’s business, operations, strategy, goals and anticipated milestones, including its ability to enroll, dose and readout data from its Phase 2b clinical trial of IMR-687 in beta-thalassemia; and other factors discussed in the “Risk Factors” section of the Company’s most recent Quarterly Report on Form 10-Q, which is on file with the Securities and Exchange Commission and in other filings that the Company makes with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.Media Contact: Gina Nugent Ten Bridge Communications 617-460-3579 gina@tenbridgecommunications.comInvestor Contact: Michael Gray 617-835-4061 mgray@imaratx.com
- 07/30/2020
|
Imara Added to Membership of U.S. Small-Cap Russell 2000® Index
- Imara Inc. (IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that it was added as a member of the U.S. small-cap Russell 2000® Index, effective after the U.S. market opens on July 1, as part of the 2020 Russell U.S. Indexes reconstitution. Membership in the Russell 2000® Index, which remains in place for one year, is based on membership in the broad-market Russell 3000® Index. “We are pleased to be added to the Russell 2000 Index following our successful IPO in March and the progress we’ve made in the months since,” said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara.
- 06/29/2020
|
Imara Announces Recipients of Real Impact Grants Program to Support People Affected by Rare Genetic Blood Disorders
- BOSTON, June 25, 2020 -- IMARA Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients.
- 06/25/2020
|
Imara Receives Orphan Drug Designation for IMR-687 for Treatment of Beta-thalassemia
- IMARA Inc. (IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for IMR-687 for the treatment of patients with beta-thalassemia. “We are pleased to receive this important designation from the FDA, which underscores the critical need for innovative new treatment options for patients with rare blood disorders such as beta-thalassemia,” said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara.
- 06/24/2020
|
Here is What Hedge Funds Think About IMARA Inc. (IMRA)
- The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
- 06/22/2020
|
Here's Why We're Not Too Worried About IMARA's (NASDAQ:IMRA) Cash Burn Situation
- There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
- 06/13/2020
|
Imara reports promising data from mid-stage trial for sickle cell treatment
- Imara Inc. announced positive interim results from a mid-stage clinical trial for its experimental sickle cell disease treatment. The Phase 2a study is testing IMR-687, an oral treatment, in adult patients; so far, a higher dose of the drug has shown a statistically significant increase in F-cells, which have fetal hemoglobin. "We know increasing fetal hemoglobin correlates with improved clinical outcomes," Imara CEO Rahul Balla said in a news release. The company's stock has soared 265.8% since it went public in mid-March, making it one of the few companies to file an initial public offering in the U.S. in the weeks leading up to stay-at-home orders as a result of the COVID-19 pandemic. The S&P; 500 is up 9.5% over the last three months.
- 06/12/2020
|
Imara Presents Positive Interim Results from Phase 2a Study of IMR-687 in Sickle Cell Disease at the Virtual European Hematology Association Annual Congress
- Imara Inc. (IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today presented interim results from its ongoing Phase 2a clinical trial of IMR-687 in adult patients with sickle cell disease (SCD) at the 25th European Hematology Association (EHA) Annual Congress. The data from this ongoing study demonstrated that IMR-687, an oral, once-a-day, potentially disease modifying treatment, was safe and well tolerated as a monotherapy and in combination with hydroxyurea (HU).
- 06/12/2020
|
Imara to Present Data on IMR-687 in Sickle Cell Disease at the 25th Annual European Hematology Association (EHA) Congress
- Imara Inc. (IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced that it will present interim data from the ongoing Phase 2a study of IMR-687 in patients with sickle cell disease at the 25th Annual European Hematology Association (EHA) Congress to be held virtually June 11-21, 2020. The data will be presented by Biree Andemariam, M.D., Associate Professor at UConn School of Medicine and Director of the New England Sickle Cell Institute at UConn Health, and lead investigator for the trial. Dr. Andemariam’s presentation (Abstract #S290), titled “IMR-687, A Highly Selective Phosphodiesterase 9 Inhibitor (PDE9I), Increases F-Cells and Fetal Hemoglobin in a Ph-2A Interim Analysis” will be included in the oral abstract session, “New Therapeutic Approaches for Sickle Cell Disease.”
- 05/21/2020
|
Imara Reports First Quarter 2020 Financial Results and Business Highlights
- Strengthened Board of Directors and expanded leadership team with appointment of General Counsel Continued progress toward initiation of Phase 2b clinical trials of IMR-687 in.
- 05/07/2020
|
Imara Launches ‘Real Impact’ Community Support Program to Address Unmet Needs Affecting People with Rare Genetic Blood Disorders
- IMARA Inc. (IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced the launch of its ‘Real Impact’ community support initiative. This program will include grant funding to support nonprofit, community-based organizations (CBOs) serving patients and families impacted by sickle cell disease (SCD) and beta-thalassemia. In 2020, Imara will fund between 15 and 20 grants totaling up to $100,000 across three key areas: social health impact programs, COVID-19 relief programs and organizational capacity enhancement programs.
- 05/06/2020
|
Imara Announces Appointment of Stephen M. Migausky as General Counsel
- Imara Inc. (IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, announced today the appointment of Stephen M. Migausky as Senior Vice President, Legal and General Counsel. In this new role, Mr. Migausky will lead the Company’s legal organization, including corporate governance and compliance functions. “As we continue to grow, prepare for later stage clinical trials, bolster the pipeline, and transition to a publicly-traded company, Steve’s expertise as a senior legal counselor will greatly benefit Imara both strategically and tactically,” said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara.
- 05/04/2020
|
The Daily Biotech Pulse: Gilead Slips Despite Forecast-Beating Q1, Moderna Partners With Lonza For Coronavirus Vaccine Production, Lyra Therapeutics IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs May 1.) * Arcturus Therapeutics Ltd (NASDAQ: ARCT) * AstraZeneca plc (NYSE: AZN) (announced an agreement with the University of Oxford for the development of
- 05/01/2020
|
The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs April 28.) * AstraZeneca plc (NYSE: AZN) * Arcturus Therapeutics Ltd (NASDAQ: ARCT) * Bio-Rad Laboratories, Inc. Class A Common Stock (NYSE: BIO) * Black Diamond
- 04/29/2020
|
The Daily Biotech Pulse: Pfizer Earnings, Roche's Spinal Muscular Dystrophy Treatment, Moderna COVID-19 Vaccine Update
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 27) * AstraZeneca plc (NYSE: AZN) * Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) * Arcturus Therapeutics Ltd (NASDAQ: ARCT) * Avadel Pharmaceuticals PLC
- 04/28/2020
|
Passage Bio (NASDAQ:IMRA) Downgraded by Zacks Investment Research
- Passage Bio (NASDAQ:IMRA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Saturday, Zacks.com reports. According to Zacks, “Imara Inc. is a biopharmaceutical company. It engages in developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of haemoglobin. The company’s […]
- 04/25/2020
|
Imara Strengthens Board of Directors With Appointment of Edward R. Conner, M.D.
- Imara Inc. (IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, today announced the appointment of Edward R. Conner, M.D., to its Board of Directors. Dr. Conner
- 04/23/2020
|
These 3 Biotechs Had Successful IPOs During the Coronavirus Crisis. Are They Buys?
- These companies just raised significant cash to advance promising drug pipelines.
- 04/23/2020
|
Keros Therapeutics Shares Climb 70% After First Post-Covid-19 Biotech IPO
- Company also exceeds offering target Continue reading...
- 04/21/2020
|
Keros Therapeutics Shares Climb 70% After First Post-Covid-19 Biotech IPO
- Keros Therapeutics Shares Climb 70% After First Post-Covid-19 Biotech IPO, Stocks: KROS,XLRN,TSE:4503,BMY,FGEN,SRRA,IMRA,ZNTL, release date:Apr 21, 2020
- 04/21/2020
|
Brokers Set Expectations for Passage Bio's Q1 2020 Earnings (NASDAQ:IMRA)
- Passage Bio (NASDAQ:IMRA) – Equities research analysts at SVB Leerink issued their Q1 2020 earnings per share estimates for Passage Bio in a report released on Monday, April 6th. SVB Leerink analyst J. Schwartz expects that the company will post earnings of ($0.69) per share for the quarter. SVB Leerink has a “Outperform” rating and […]
- 04/09/2020
|
Zacks: Brokerages Set $30.00 Price Target for Passage Bio (NASDAQ:IMRA)
- Passage Bio (NASDAQ:IMRA) has been given an average broker rating score of 1.25 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. One investment analyst has rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. Analysts have set a […]
- 04/08/2020
|
Passage Bio (NASDAQ:IMRA) Coverage Initiated at Cowen
- Research analysts at Cowen began coverage on shares of Passage Bio (NASDAQ:IMRA) in a report issued on Monday, Briefing.com Automated Import reports. The brokerage set an “outperform” rating and a $25.00 price target on the stock. Cowen’s price target would suggest a potential upside of 56.35% from the stock’s previous close. IMRA has been the […]
- 04/08/2020
|
Fly Intel: Top five analyst initiations JAZZ;CLAR;IMRA;IDYA;SLAB
- Fly Intel: Top five analyst initiations JAZZ CLAR IMRA IDYA SLAB
- 04/06/2020
|
Passage Bio (NASDAQ:IMRA) Coverage Initiated by Analysts at Morgan Stanley
- Equities researchers at Morgan Stanley assumed coverage on shares of Passage Bio (NASDAQ:IMRA) in a report issued on Monday, Briefing.com Automated Import reports. The firm set an “overweight” rating and a $35.00 price target on the stock. Morgan Stanley’s price objective suggests a potential upside of 122.22% from the company’s current price. IMRA opened at […]
- 04/06/2020
|
The Week Ahead In Biotech: Spotlight On Q1 Pre-Announcements As COVID-19 Continues To Disrupt Operations
- Biotech stocks went along with the broader market flow in the week ended April 3, with the COVID-19 pandemic dictating sentiment. The week witnessed a host of clinical readouts and pre-announcements in light of the COVID-19 impact.The stock that made headlines during the week was Amarin Corporation plc
- 04/05/2020
|
Best ETFs for 2020: The Renaissance IPO ETF Got Major Help From Zoom
- The Renaissance IPO ETF could be one of the best ETFs this year as some of its holdings can soften the blow from the coronavirus pandemic.
- 03/27/2020
|
Investors Shaken by Coronavirus Sow Seeds of M&A, Financing Slowdown
- The coronavirus pandemic is narrowing the avenues open to biotechs for financing their endeavors, according to some industry veterans. “I think that fear
- 03/23/2020
|
The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 19.) * Biomerica, Inc. (NASDAQ: BMRA) * Centogene NV (NASDAQ: CNTG) * Gilead Sciences, Inc. (NASDAQ: GILD) * Imara Inc (NASDAQ: IMRA) * Regeneron Pharmaceuticals
- 03/20/2020
|
Bio Roundup: Pandemic Declared, Rubius Restarts, Kymera’s Cash & More
- The financial markets are tumbling, event cancellations are mounting, and sports leagues are suspending their seasons. March Madness is in full swing but
- 03/13/2020
|
IMARA Announces Pricing of Initial Public Offering
- IMARA Inc. (the “Company”) (IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, known as hemoglobinopathies, announced the pricing of its initial public offering
- 03/12/2020
|
